Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 2
1947 2
1953 2
1954 1
1955 2
1957 5
1958 1
1959 3
1960 5
1961 7
1962 4
1963 4
1964 3
1965 8
1966 8
1967 12
1968 8
1969 13
1970 7
1971 12
1972 7
1973 10
1974 13
1975 15
1976 12
1977 25
1978 22
1979 18
1980 26
1981 25
1982 23
1983 27
1984 21
1985 24
1986 23
1987 44
1988 41
1989 29
1990 47
1991 58
1992 69
1993 75
1994 66
1995 70
1996 84
1997 77
1998 66
1999 81
2000 75
2001 103
2002 97
2003 91
2004 91
2005 83
2006 75
2007 94
2008 84
2009 85
2010 103
2011 120
2012 111
2013 152
2014 158
2015 172
2016 170
2017 193
2018 207
2019 224
2020 169
Text availability
Article attribute
Article type
Publication date

Search Results

3,621 results
Results by year
Filters applied: . Clear all
Page 1
Regulation of macrophage immunometabolism in atherosclerosis.
Koelwyn GJ, Corr EM, Erbay E, Moore KJ. Koelwyn GJ, et al. Among authors: Moore KJ. Nat Immunol. 2018 Jun;19(6):526-537. doi: 10.1038/s41590-018-0113-3. Epub 2018 May 18. Nat Immunol. 2018. PMID: 29777212 Free PMC article. Review.
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P. Moore K, et al. N Engl J Med. 2018 Dec 27;379(26):2495-2505. doi: 10.1056/NEJMoa1810858. Epub 2018 Oct 21. N Engl J Med. 2018. PMID: 30345884 Clinical Trial.
Olaparib in the treatment of ovarian cancer.
Washington CR, Richardson DL, Moore KN. Washington CR, et al. Among authors: Moore KN. Future Oncol. 2019 Oct;15(30):3435-3449. doi: 10.2217/fon-2019-0271. Epub 2019 Sep 3. Future Oncol. 2019. PMID: 31478762 Review.
Antibody-Drug Conjugate-Based Therapeutics: State of the Science.
Birrer MJ, Moore KN, Betella I, Bates RC. Birrer MJ, et al. Among authors: Moore KN. J Natl Cancer Inst. 2019 Jun 1;111(6):538-549. doi: 10.1093/jnci/djz035. J Natl Cancer Inst. 2019. PMID: 30859213 Review.
Pancreatic cancer organoids recapitulate disease and allow personalized drug screening.
Driehuis E, van Hoeck A, Moore K, Kolders S, Francies HE, Gulersonmez MC, Stigter ECA, Burgering B, Geurts V, Gracanin A, Bounova G, Morsink FH, Vries R, Boj S, van Es J, Offerhaus GJA, Kranenburg O, Garnett MJ, Wessels L, Cuppen E, Brosens LAA, Clevers H. Driehuis E, et al. Among authors: Moore K. Proc Natl Acad Sci U S A. 2019 Dec 9;116(52):26580-90. doi: 10.1073/pnas.1911273116. Online ahead of print. Proc Natl Acad Sci U S A. 2019. PMID: 31818951 Free PMC article.
Cholesterol Efflux Pathways Suppress Inflammasome Activation, NETosis, and Atherogenesis.
Westerterp M, Fotakis P, Ouimet M, Bochem AE, Zhang H, Molusky MM, Wang W, Abramowicz S, la Bastide-van Gemert S, Wang N, Welch CL, Reilly MP, Stroes ES, Moore KJ, Tall AR. Westerterp M, et al. Among authors: Moore KJ. Circulation. 2018 Aug 28;138(9):898-912. doi: 10.1161/CIRCULATIONAHA.117.032636. Circulation. 2018. PMID: 29588315 Free PMC article.
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, Wahner Hendrickson AE, Azodi M, DiSilvestro P, Oza AM, Cristea M, Berek JS, Chan JK, Rimel BJ, Matei DE, Li Y, Sun K, Luptakova K, Matulonis UA, Monk BJ. Moore KN, et al. Lancet Oncol. 2019 May;20(5):636-648. doi: 10.1016/S1470-2045(19)30029-4. Epub 2019 Apr 1. Lancet Oncol. 2019. PMID: 30948273 Clinical Trial.
Niraparib for the treatment of ovarian cancer.
Essel KG, Moore KN. Essel KG, et al. Among authors: Moore KN. Expert Rev Anticancer Ther. 2018 Aug;18(8):727-733. doi: 10.1080/14737140.2018.1490180. Epub 2018 Jul 2. Expert Rev Anticancer Ther. 2018. PMID: 29911447 Review.
3,621 results
Jump to page
Feedback